NCT03572582View on ClinicalTrials.gov

Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

June 14, 2018

Primary Completion Date

October 12, 2021

Study Completion Date

December 10, 2021

Conditions
Carcinoma, HepatocellularHepatic CarcinomaHepatocellular Cancer
Interventions
DRUG

Nivolumab

Nivolumab therapy combined with standard TACE treatment

DRUG

TACE

TACE is performed by using drug eluting beads

Trial Locations (1)

30625

Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie & Endokrinologie, Hanover

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

AIO-Studien-gGmbH

OTHER